BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 31543165)

  • 1. Total IN.PACT drug-coated balloon initiative reporting pooled imaging and propensity-matched cohorts.
    Shishehbor MH; Schneider PA; Zeller T; Razavi MK; Laird JR; Wang H; Tieché C; Parikh SA; Iida O; Jaff MR
    J Vasc Surg; 2019 Oct; 70(4):1177-1191.e9. PubMed ID: 31543165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-Term Clinical Effectiveness of a Drug-Coated Balloon for the Treatment of Femoropopliteal Lesions.
    Laird JA; Schneider PA; Jaff MR; Brodmann M; Zeller T; Metzger DC; Krishnan P; Scheinert D; Micari A; Wang H; Masters M; Tepe G
    Circ Cardiovasc Interv; 2019 Jun; 12(6):e007702. PubMed ID: 31195825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug-Coated Balloon vs Standard Percutaneous Transluminal Angioplasty for the Treatment of Atherosclerotic Lesions in the Superficial Femoral and Proximal Popliteal Arteries: One-Year Results of the MDT-2113 SFA Japan Randomized Trial.
    Iida O; Soga Y; Urasawa K; Saito S; Jaff MR; Wang H; Ookubo H; Yokoi H;
    J Endovasc Ther; 2018 Feb; 25(1):109-117. PubMed ID: 29264999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment Effect of Drug-Coated Balloons Is Durable to 3 Years in the Femoropopliteal Arteries: Long-Term Results of the IN.PACT SFA Randomized Trial.
    Schneider PA; Laird JR; Tepe G; Brodmann M; Zeller T; Scheinert D; Metzger C; Micari A; Sachar R; Jaff MR; Wang H; Hasenbank MS; Krishnan P;
    Circ Cardiovasc Interv; 2018 Jan; 11(1):e005891. PubMed ID: 29326153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug-coated balloon versus uncoated percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal artery: 2-year results of the MDT-2113 SFA Japan randomized trial.
    Iida O; Soga Y; Urasawa K; Saito S; Jaff MR; Wang H; Ookubo H; Yokoi H;
    Catheter Cardiovasc Interv; 2019 Mar; 93(4):664-672. PubMed ID: 30747489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. German Center Subanalysis of the LEVANT 2 Global Randomized Study of the Lutonix Drug-Coated Balloon in the Treatment of Femoropopliteal Occlusive Disease.
    Scheinert D; Schmidt A; Zeller T; Müller-Hülsbeck S; Sixt S; Schröder H; Weiss N; Ketelsen D; Ricke J; Steiner S; Rosenfield K
    J Endovasc Ther; 2016 Jun; 23(3):409-16. PubMed ID: 27117972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The IN.PACT DEEP Clinical Drug-Coated Balloon Trial: 5-Year Outcomes.
    Zeller T; Micari A; Scheinert D; Baumgartner I; Bosiers M; Vermassen FEG; Banyai M; Shishehbor MH; Wang H; Brodmann M;
    JACC Cardiovasc Interv; 2020 Feb; 13(4):431-443. PubMed ID: 32081236
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-Coated Balloon Angioplasty Compared With Uncoated Balloons in the Treatment of 200 Chinese Patients With Severe Femoropopliteal Lesions: 24-Month Results of AcoArt I.
    Xu Y; Jia X; Zhang J; Zhuang B; Fu W; Wu D; Wang F; Zhao Y; Guo P; Bi W; Wang S; Guo W
    JACC Cardiovasc Interv; 2018 Dec; 11(23):2347-2353. PubMed ID: 30448170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-Effectiveness of Endovascular Femoropopliteal Intervention Using Drug-Coated Balloons Versus Standard Percutaneous Transluminal Angioplasty: Results From the IN.PACT SFA II Trial.
    Salisbury AC; Li H; Vilain KR; Jaff MR; Schneider PA; Laird JR; Cohen DJ
    JACC Cardiovasc Interv; 2016 Nov; 9(22):2343-2352. PubMed ID: 27884360
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustainable Antirestenosis Effect With a Low-Dose Drug-Coated Balloon: The ILLUMENATE European Randomized Clinical Trial 2-Year Results.
    Brodmann M; Werner M; Meyer DR; Reimer P; Krüger K; Granada JF; Jaff MR; Schroeder H;
    JACC Cardiovasc Interv; 2018 Dec; 11(23):2357-2364. PubMed ID: 30522663
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IN.PACT SFA Clinical Study Using the IN.PACT Admiral Drug-Coated Balloon in a Chinese Patient Population.
    Chen Z; Guo W; Jiang W; Wang F; Fu W; Zou Y; Deckers S; Li P; Popma JJ; Jaff MR
    J Endovasc Ther; 2019 Aug; 26(4):471-478. PubMed ID: 31204595
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease: The IN.PACT Global Study De Novo In-Stent Restenosis Imaging Cohort.
    Brodmann M; Keirse K; Scheinert D; Spak L; Jaff MR; Schmahl R; Li P; Zeller T;
    JACC Cardiovasc Interv; 2017 Oct; 10(20):2113-2123. PubMed ID: 29050631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcomes with Jetstream atherectomy with or without drug coated balloons in treating femoropopliteal arteries: A single center experience (JET-SCE).
    Shammas NW; Shammas GA; Jones-Miller S; Shammas WJ; Bou-Dargham B; Shammas AN; Banerjee S; Rachwan RJ; Daher GE
    Cardiovasc Revasc Med; 2018 Oct; 19(7 Pt A):771-777. PubMed ID: 30420096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel exposure: Long-term safety and effectiveness of a drug-coated balloon for claudication in pooled randomized trials.
    Schneider PA; Brodmann M; Mauri L; Laird J; Soga Y; Micari A; Ansel G; Shishehbor MH; Krishnan P; Gao Q; Ouriel K; Zeller T
    Catheter Cardiovasc Interv; 2020 Nov; 96(5):1087-1099. PubMed ID: 32830913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Three-Year Results of the IN.PACT SFA Japan Trial Comparing Drug-Coated Balloons With Percutaneous Transluminal Angioplasty.
    Soga Y; Iida O; Urasawa K; Saito S; Jaff MR; Wang H; Ookubo H; Yokoi H
    J Endovasc Ther; 2020 Dec; 27(6):946-955. PubMed ID: 32865145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stellarex Drug-Coated Balloon for Treatment of Femoropopliteal Disease: Twelve-Month Outcomes From the Randomized ILLUMENATE Pivotal and Pharmacokinetic Studies.
    Krishnan P; Faries P; Niazi K; Jain A; Sachar R; Bachinsky WB; Cardenas J; Werner M; Brodmann M; Mustapha JA; Mena-Hurtado C; Jaff MR; Holden AH; Lyden SP
    Circulation; 2017 Sep; 136(12):1102-1113. PubMed ID: 28729250
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Total IN.PACT All-Subjects One-Year Analysis and Standard vs Broader Implications.
    Kobe DS; Jaff MR; Zeller T; Schneider PA; Shishehbor MH
    J Invasive Cardiol; 2020 Jul; 32(7):243-248. PubMed ID: 32610266
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug-Coated Balloon Treatment for Femoropopliteal Artery Disease.
    Scheinert D; Micari A; Brodmann M; Tepe G; Peeters P; Jaff MR; Wang H; Schmahl R; Zeller T;
    Circ Cardiovasc Interv; 2018 Oct; 11(10):e005654. PubMed ID: 30354636
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of adjunctive drug-coated balloon therapy in endovascular treatment of common femoral artery disease.
    Imran HM; Hyder ON; Soukas PA
    Cardiovasc Revasc Med; 2019 Mar; 20(3):210-214. PubMed ID: 29970328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Pilot Study of Femoropopliteal Artery Revascularisation with a Low Dose Paclitaxel Coated Balloon: Is Predilatation Necessary?
    Schroeder H; Meyer DR; Lux B; Ruecker F; Martorana M; Miller LE; Duda S
    Eur J Vasc Endovasc Surg; 2017 Sep; 54(3):348-355. PubMed ID: 28778456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.